MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Schizophrenia is a debilitating mental disorder, affecting more than 30 million people worldwide. As a multifactorial disease, the underlying causes of schizophrenia require analysis by multiplex methods such as proteomics to allow identification of whole protein networks. Previous post-mortem proteomic studies on brain tissues from schizophrenia patients have demonstrated changes in activation of glycolytic and energy metabolism pathways. However, it is not known whether these changes occur in neurons or in glial cells. To address this question, we treated neuronal, astrocyte, and oligodendrocyte cell lines with the NMDA receptor antagonist MK-801 and measured the levels of six glycolytic enzymes by Western blot analysis. MK-801 acts on the glutamatergic system and has been proposed as a pharmacological means of modeling schizophrenia. Treatment with MK-801 resulted in significant changes in the levels of glycolytic enzymes in all cell types. Most of the differences were found in oligodendrocytes, which had altered levels of hexokinase 1 (HK1), enolase 2 (ENO2), phosphoglycerate kinase (PGK), and phosphoglycerate mutase 1 after acute MK-801 treatment (8 h), and HK1, ENO2, PGK, and triosephosphate isomerase (TPI) following long term treatment (72 h). Addition of the antipsychotic clozapine to the cultures resulted in counter-regulatory effects to the MK-801 treatment by normalizing the levels of ENO2 and PGK in both the acute and long term cultures. In astrocytes, MK-801 affected only aldolase C (ALDOC) under both acute conditions and HK1 and ALDOC following long term treatment, and TPI was the only enzyme affected under long term conditions in the neuronal cells. In conclusion, MK-801 affects glycolysis in oligodendrocytes to a larger extent than neuronal cells and this may be modulated by antipsychotic treatment. Although cell culture studies do not necessarily reflect the in vivo pathophysiology and drug effects within the brain, these results suggest that neurons, astrocytes, and oligodendrocytes are affected differently in schizophrenia. Employing in vitro models using neurotransmitter agonists and antagonists may provide new insights about the pathophysiology of schizophrenia which could lead to a novel system for drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Oligodendroglia metabolically support axons and contribute to neurodegeneration
Lee, Y., Morrison, B. M., Li, Y., Lengacher, S., Farah, M. H., Hoffman, P. N., Liu, Y., Tsingalia, A., Jin, L., Zhang, P.-W., et al. (2012) · Nature · doi:10.1038/nature11314 · Cited by 1,664
Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
Stephan, K. E., Friston, K. J., & Frith, C. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn176 · Cited by 1,134 · cited 2×
“…Paulo, Brazil, 9 Department of Translational Research in Psychiatry Proteomics and Biomarkers, Max Planck Institute of Psychiatry, Munich, Germany, 10 UNICAMP’s Neurobiology Center, Campinas, Brazil Schizophrenia is a debilitating mental disorder, affecting more than 30 million people worldwide.”
BackgroundPennington, K., Beasley, C. L., Dicker, P., Fagan, A., English, J., Pariante, C. M., Wait, R., Dunn, M. J., & Cotter, D. R. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002098 · Cited by 227 · cited 1×
“…et al., 2009, 2011; Martins-de-Souza et al., 2011a), neuronal structure and transport (Carlino et al., 2011; Chan et al., 2011; English et al., 2011), and cell trafficking and signal transduction (Pennington et al., 2008; English et al., 2011; Föcking et al., 2011;Martins-de-Souza et al., 2011a).”
BackgroundAgger, S. A., Marney, L. C., & Hoofnagle, A. N. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.152264 · Cited by 143 · cited 1×
“…investigations, including screening the levels of dihydroartemisinin (DHA) in plasma of malaria patients (Wiesner et al., 2011), measuring the levels of apolipoproteins in human plasma (Agger et al., 2010) and in cancer biomarker screening studies (Ang and Nice, 2010; Welinder et al., 2014).”
BackgroundMartins-de-Souza, D., Harris, L. W., Guest, P. C., & Bahn, S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3459 · Cited by 134 · cited 1×
“…Fukui, Japan, 4 Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 5 Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan, 6 Department of Psychiatry and Psychotherapy–Center for Behavioral Brain Sciences,…”
BackgroundSelf-citationAmyloid-β Triggers the Release of Neuronal Hexokinase 1 from Mitochondria
Saraiva, L. M., Seixas da Silva, G. S., Galina, A., da-Silva, W. S., Klein, W. L., Ferreira, S. T., & De Felice, F. G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015230 · Cited by 94
Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia
Martins-de-Souza, D. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.07.007 · Cited by 81
Self-citationRoberts, R. C., Roche, J. K., & McCullumsmith, R. E. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.07.019 · Cited by 76 · cited 1×
“…but the findings or recent studies suggest that this could occur through MK-801-induced disruption of glutamate transporters which are associated with mitochondria and energy metabolism enzymes, as found in glial cells and neurons (Domercq et al., 2007; Jackson et al., 2014; Roberts et al., 2014).”
Background
Cited by
Zuccoli, G. S., Saia-Cereda, V. M., Nascimento, J. M., & Martins-de-Souza, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00493 · Cited by 157
“Notably, of the three cell types, oligodendrocytes were the ones with more metabolic differences (Guest et al., 2015).”
BackgroundSelf-citationVikhreva, O. V., Rakhmanova, V. I., Orlovskaya, D. D., & Uranova, N. A. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.04.023 · Cited by 82
“Treatment of oligodendrocyte cell lines with the NMDA receptor antagonist MK-801 resulted in significant changes in the levels of glycolytic enzymes, especially in oligodendorocytes (Guest et al., 2015).”
BackgroundWeng, W., Chen, Y., Wang, M., Zhuang, Y., & Behnisch, T. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00247 · Cited by 14
Metadata
- Authors
- Guest, P. C., Iwata, K., Kato, T. A., Steiner, J., Schmitt, A., Turck, C. W., & Martins-de-Souza, D.
- Venue
- Frontiers in Cellular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-05-12
- Volume
- 09
- Pages
- 180-180
- ISSN
- 1662-5102 (ISSN-L)
- OpenAlex
- W1892160302
- Cited by
- 53
- References
- 9
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.